Passage Bio (PASG) Set to Post Quarterly Earnings on Monday

Passage Bio (NASDAQ:PASG) is anticipated to announce its Q3 2026 resultson Monday, November 9th. Analysts expect Passage Bio to post earnings of ($2.43) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG) last released its earnings results on Monday, August 10th. The company reported ($2.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($2.44). On average, analysts expect Passage Bio to post ($9.78) EPS for the current fiscal year and ($10.20) EPS for the next fiscal year.

Passage Bio Stock Performance

Shares of NASDAQ PASG opened at $3.45 on Monday. Passage Bio has a 52-week low of $3.29 and a 52-week high of $20.00. The firm has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.30 and a beta of 1.40. The stock has a 50 day moving average price of $4.27 and a 200 day moving average price of $6.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PASG shares. Weiss Ratings downgraded Passage Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Passage Bio from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Passage Bio currently has a consensus rating of “Hold” and a consensus target price of $13.25.

Passage Bio Company Profile

Passage Bio, Inc is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders.

Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene.